Literature DB >> 3101233

Cerebrovascular ischemia associated with lupus anticoagulant.

S R Levine, K M Welch.   

Abstract

The lupus anticoagulant, an acquired circulating serum gamma-globulin, prolongs all phospholipid-dependent coagulation tests. Recent associations of the lupus anticoagulant and focal cerebral and/or ocular ischemia have been made. We present 5 cases of lupus anticoagulant-associated cerebrovascular ischemia and review all reported cases for the first time. Clinical spectra, cerebral angiographic findings, associated conditions, and response to therapy are presented. Typical features include a relatively young age (mean 39 years), female preponderance, transient ischemic attacks (including amaurosis fugax) or stroke, and normal or large vessel occlusions on angiography. Commonly associated conditions were systemic lupus erythematosus (34%), noncerebral venous thrombosis (31%), hypertension (28%), false-positive VDRL (28%), and spontaneous abortions (22%). Four of our 5 patients (all without systemic lupus erythematosus) and 11 of the 20 (55%) patients in the literature without systemic lupus erythematosus had other definite stroke risk factors coexisting. Response to therapy was highly variable, with no clear beneficial effect of corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101233     DOI: 10.1161/01.str.18.1.257

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

1.  Prevalence of anticardiolipin antibodies in the elderly British population.

Authors:  K K Chakravarty; R E Gray; M Webley; M A Byron; J Wozniak
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

2.  Retinal migraine, chorea, and retinal artery thrombosis in a patient with primary antiphospholipid antibody syndrome.

Authors:  J A Gutrecht; N Kattwinkel; M J Stillman
Journal:  J Neurol       Date:  1991-02       Impact factor: 4.849

Review 3.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Stroke in young people--the heart of the matter.

Authors:  R G Hart; G L Freeman
Journal:  West J Med       Date:  1987-05

5.  Ischaemic optic neuropathy, transverse myelitis, and epilepsy in an anti-phospholipid positive patient with systemic lupus erythematosus.

Authors:  M F Cordeiro; M E Lloyd; D J Spalton; G R Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

6.  Primary antiphospholipid syndrome (PAPS). Two case reports and therapeutic implications.

Authors:  J A Rump; B Lang; H Engler; H H Peter
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

7.  Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum.

Authors:  K H Sun; W T Liu; C Y Tsai; T S Liao; W M Lin; C L Yu
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

8.  Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids.

Authors:  H S Markus; N Hopkinson
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

Review 9.  Diagnosis and pathogenesis of CNS lupus.

Authors:  A P van Dam
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

10.  Antiphospholipid antibodies syndrome and cerebral ischemia.

Authors:  S Severi; M Ghezzi; M Felici; A Miele
Journal:  Ital J Neurol Sci       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.